SAN DIEGO, November 04, 2026--Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the third quarter ended September 30, 2026, together with other business updates.
Maravai LifeSciences (NASDAQ:MRVI) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you by
Maravai LifeSciences (NASDAQ:MRVI) enters 2026 at a strategic inflection point, balancing its post-pandemic operational transition against a core business model rooted in high-margin nucleic acid production and bioprocess impurity testing. With a market capitalization hovering near $2 billion against full-year revenue guidance of $205 million to $215 million, the company carries a structured balance sheet […]
Maravai LifeSciences Holdings has seen its share price swing sharply in recent years, which raises a straightforward question for anyone looking at the stock today. Is the current US$7.65 price supported by the cash flows the business can generate over time, based on a Discounted Cash Flow (DCF) view of its intrinsic value? The stock has delivered a 171.3% return over the past year, which puts real pressure on the question of whether that move is fully backed by the cash the business is...
Maravai LifeSciences Holdings (MRVI) has been drawing attention after recent share price swings, with the stock closing at US$7.37 on 24 September 2026. Investors are weighing mixed return patterns across different holding periods. Recent trading in Maravai LifeSciences Holdings has been choppy, with a 7-day share price return of 7.75% but a 30-day move that is down 12.57%, while the 90-day gain of 20.42% and year to date share price return of 116.76% signal momentum that has cooled recently...
Detailed price information for Thermo Fisher Scientific (TMO-N) from The Globe and Mail including charting and trades.
Detailed price information for Maravai Lifesciences Holdings Inc Cl A (MRVI-Q) from The Globe and Mail including charting and trades.
Maravai Lifesciences Holdings (MRVI) has an average rating of overweight and mean price target of $5
This is the newest page. Registered accounts read further back.